
    
      This research study is a Phase Ib clinical trial. It will assess the Safety, tolerability,
      and feasibility of gemcitabine-nab paclitaxel alternating with nal-IRI/5FU/leucovorin
      (NAPOLI) in de novo resectable and borderline resectable pancreatic cancer.

      Subjects must have a newly diagnosed resectable or borderline resectable pancreatic ductal
      cancer and meet all inclusion/exclusion criteria.

      Treatment consists of 4 week treatment cycles. Nab-paclitaxel and gemcitabine will be
      administered on days 1,8, and 15 with NAPOLI will be administered on days 1 and 15.
    
  